We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: albuminuria
MedXY News
EnglishTag

albuminuria

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights
Cardiologyacoramidisalbuminuria

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights

By MedXY|Jul 3, 2026

Acoramidis stabilizes transthyretin and shows kidney-protective effects in transthyretin amyloid cardiomyopathy by reducing eGFR decline and albuminuria, with an initial reversible dip in kidney function associated with improved clinical ou

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT
Diabetes & Endocrinologyalbuminuria
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
chronic kidney disease

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT

By MedXY|May 12, 2026

In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
Diabetes & Endocrinologyalbuminuriachronic kidney disease

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

By MedXY|Feb 9, 2026

A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety
Diabetes & Endocrinologyalbuminuriachronic kidney disease

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

By MedXY|Nov 28, 2025

The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.

Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials
NephrologyalbuminuriaCKD

Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials

By MedXY|Nov 13, 2025

Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chroni

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Diabetes & EndocrinologyalbuminuriaCKD

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

By MedXY|Nov 9, 2025

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation
Diabetes & Endocrinologyalbuminuriachronic kidney disease

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

By MedXY|Nov 8, 2025

A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria
Diabetes & Endocrinologyalbuminuriachronic kidney disease

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

By MedXY|Nov 8, 2025

A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities